Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: VCEL

Vericel Corporation

Healthcare | Biotechnology

No licensed closing price on file for VCEL. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$0.48

Vericel Corporation (NASDAQ: VCEL) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 13:31 UTC.

What Vericel Corporation does

Vericel Corporation is a biopharmaceutical company that develops and markets cell therapy and specialty biologic products for sports medicine and severe burn care. The company's main products include MACI, an autologous cell therapy for repairing knee cartilage defects that recently gained FDA approval for arthroscopic delivery; Epicel, a permanent skin replacement for severe burns; and NexoBrid, a topically applied biological product for burn treatment that Vericel licenses from another company.

Summarized from Vericel Corporation’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation
EPS (TTM)$0.48
Return on equity4.66%

Revenue, margins & earnings

FY2021: net loss $7M on revenue $156M$156MFY2021FY2022: net loss $17M on revenue $164M$164MFY2022FY2023: net loss $3M on revenue $198M$198MFY2023FY2024 Revenue: $237M — margin split not shown (non-operating gains)$237MFY2024FY2025 Revenue: $276M — margin split not shown (non-operating gains)$276MFY2025
  • Net income
  • Taxes & interest
  • Operating expenses
  • Cost of revenue
  • Net loss year
Annual revenue; bands show net, operating, gross margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-08-14
  • 2026-08-14DirectorOption exercise7,000$91.3K
  • 2026-08-14DirectorSale-7,000$311.7K
  • 2026-08-14DirectorStock Option (Right to Buy)Option exercise7,000—
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Vericel Corporation do?

Vericel Corporation is a biopharmaceutical company that develops and markets cell therapy and specialty biologic products for sports medicine and severe burn care.

When did VCEL last file with the SEC?

Vericel Corporation's most recent SEC filing on record is a 8-K filed 2026-05-18. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 13:31 UTC. This page is also available as JSON at /api/data?ticker=VCEL and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for VCEL and 5,000+ tickers.

Create a free account — keep VCEL
For your agent
GET /api/data?ticker=VCEL

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt